https://pimpathway.com/once-th....e-proceeding-will-ge
BACKGROUND (+)-SJ000557733 (SJ733) is a novel, orally bioavailable inhibitor of Plasmodium falciparum ATP4. In this first-in-human and induced blood-stage malaria phase 1a/b trial, we investigated the security, tolerability, pharmacokinetics, and antimalarial activity of SJ733 in humans. TECHNIQUES The phase 1a had been a single-centre, dose-escalation, first-in-human study of SJ733 allowing modifications to dose increments and dose-cohort dimensions on the basis of safety and pharmacokinetic outcomes. The
Like
Comment
Share
